In summary, these findings suggest that targeting HSC reprogramming by attenuation of DNMT3B expression in the tumor environment might represent a promising therapeutic strategy for liver fibrosis and HCC. The gene discussed is DNMT3B; the disease is hepatocellular carcinoma.